For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- New Product Launches “On Track,” Sales Brisk: Otsuka Holdings Pres. Higuchi
March 22, 2013
- SSRI Predicts SGLT-2 Inhibitor Market to Grow to around 60 Billion Yen in 5th Year after Launch
March 22, 2013
- Japan Pharmas Accelerating Drives to Set Up Medical Affairs Units
March 21, 2013
- MHLW Lifts All-Case Surveillance for Treakisym: SymBio, Eisai
March 19, 2013
- Alcon Japan, Kyowa Kirin Adjust Shipments of Anti-Allergy Drugs
March 19, 2013
- Daiichi Sankyo to File Prasugrel for Cardiovascular Disease in PCI Patients in Japan
March 19, 2013
- Pfizer Japan Launches OAB Treatment Toviaz
March 19, 2013
- Generic Companies Increasing Focus on Fast-growing Oncology Market; Shift to Overseas Production Will Spur Cost Competition
March 18, 2013
- Eisai Appoints Its First Female Executive
March 18, 2013
- MHLW Lifts All-Case Surveillance for Novartis' Lucentis
March 18, 2013
- Nihon Pharmaceutical Industry Voluntarily Recalls Revinbace Tablets 10 mg, Temporarily Suspends Sales
March 18, 2013
- Eisai Eyes Sales of 50 Billion Yen in Asian Generic Biz within 5 Years
March 15, 2013
- Shionogi, Kyoto University to Collaborate on Research for AD Treatment
March 15, 2013
- Eli Lilly Japan Files Tadalafil for BPH, 3rd NDA for Same API
March 15, 2013
- Astellas Files NDA in Japan for SGLT-2 Inhibitor Ipragliflozin
March 15, 2013
- API Corporation to Establish Production Base for Drug Substances, Intermediates in India
March 15, 2013
- Astellas Grants US Firm Global Rights to Ceftolozane
March 14, 2013
- Eli Lilly Japan’s 2012 Sales Surge 10% on Brisk Zyprexa; NHI Price Cut Countered
March 14, 2013
- Sanofi Japan Aims to Enhance Leadership Status in Diabetes Sector with GLP-1, President Says
March 14, 2013
- A Number of Blockbuster Candidates Emerging from Japanese Pharmas’ In-house R&D: Dr Nakamura of Pharma Forum Institute
March 14, 2013
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…